Compare HFFG & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | ALDX |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | 960 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.8M | 101.1M |
| IPO Year | 2016 | 2014 |
| Metric | HFFG | ALDX |
|---|---|---|
| Price | $1.87 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $6.00 | $5.50 |
| AVG Volume (30 Days) | 129.2K | ★ 914.4K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.65 | ★ 40.43 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,228,282,000.00 | N/A |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $92.00 | ★ N/A |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $1.38 | $1.07 |
| 52 Week High | $3.86 | $6.18 |
| Indicator | HFFG | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 52.21 |
| Support Level | $1.73 | $1.49 |
| Resistance Level | $2.30 | $1.88 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 14.75 | 64.71 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.